Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma × belzutifan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 21 Kidney Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 4 Pheochromocytoma 2 Paraganglioma 2 Neoplasm Metastasis 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Hemangioblastoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Cisplatin 43 Carboplatin 38 pembrolizumab 36 Paclitaxel 32 Gemcitabine 27 Pemetrexed 18 Radiotherapy 17 Magnetic Resonance Spectroscopy 17 Radiotherapy, Intensity-Modulated 16 Docetaxel 16 Cetuximab 15 Nivolumab 14 Specimen Handling 13 Cyclophosphamide 13 durvalumab 12 Fluorouracil 12 130-nm albumin-bound paclitaxel 10 Platinum 9 osimertinib 8 Sunitinib 8 Sorafenib 8 Radiation 8 Bevacizumab 8 1,2-diaminocyclohexaneplatinum II citrate 8 Oxaliplatin 7 Irinotecan 7 Everolimus 7 Drug Therapy 7 Capecitabine 7 fludarabine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07227402 2026-03-16

LITESPARK-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡